Literature DB >> 18575860

Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia.

Constanze Sommer1, Herwig Lackner, Martin Benesch, Petra Sovinz, Wolfgang Schwinger, Andrea Moser, Jutta Bergloeff, Anna Gruber, Christian Urban.   

Abstract

Three adolescents with central nervous system (CNS) negative acute myeloid leukaemia (AML) refused cranial irradiation for CNS prophylaxis. Instead, these patients received four doses of 50 mg of intrathecal (IT) liposomal cytarabine on day 1, 15, 43 and 71 of maintenance therapy. Corticosteroids were given to prevent chemical arachnoiditis. All patients developed bilateral papilloedema after the third or fourth dose of liposomal cytarabine, local side effects were observed in two patients. Under prolonged dexamethasone therapy, side effects resolved completely. As reversible neuroophthalmological side effects caused by intrathecal liposomal cytarabine can also be observed under low-dose maintenance therapy in patients with CNS negative AML, it should be used with caution in children and adolescents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18575860     DOI: 10.1007/s00277-008-0521-9

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  8 in total

1.  Intracranial hypertension following intrathecal administration of liposomal cytarabine.

Authors:  S Lunskens; L Lammertijn; D Deeren; B Bergmans; J Maertens; R Vandenberghe
Journal:  J Neurol       Date:  2010-08-13       Impact factor: 4.849

2.  Efficacy and safety of liposomal cytarabine in children with primary CNS tumours with leptomeningeal involvement.

Authors:  A Navajas; A Lassaletta; A Morales; B López-Ibor; C Sábado; C Moscardó; E Mateos; J Molina; M Sagaseta; A Sastre
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

3.  Neurologic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin lymphoma.

Authors:  Jaime Gállego Pérez-Larraya; José Alberto Palma; María Carmona-Iragui; Roberto Fernández-Torrón; Pablo Irimia; Paula Rodríguez-Otero; Carlos Panizo; Eduardo Martínez-Vila
Journal:  J Neurooncol       Date:  2010-10-17       Impact factor: 4.130

4.  Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma.

Authors:  Nicola Gökbuget; Christina-Maria Hartog; Renato Bassan; Heinz-Gerd Derigs; Herve Dombret; Richard Greil; Jesus-Maria Hernández-Rivas; Francoise Huguet; Tamara Intermesoli; Eric Jourdan; Christian Junghanss; Lothar Leimer; Maria-Jose Moreno; Albrecht Reichle; Josep Ribera; Matthias Schmid; Hubert Serve; Matthias Stelljes; Reingard Stuhlmann; Dieter Hoelzer
Journal:  Haematologica       Date:  2010-10-15       Impact factor: 9.941

Review 5.  The leptomeninges as a critical organ for normal CNS development and function: First patient and public involved systematic review of arachnoiditis (chronic meningitis).

Authors:  Carol S Palackdkharry; Stephanie Wottrich; Erin Dienes; Mohamad Bydon; Michael P Steinmetz; Vincent C Traynelis
Journal:  PLoS One       Date:  2022-09-30       Impact factor: 3.752

6.  Intrathecal liposomal cytarabine in children under 4 years with malignant brain tumors.

Authors:  Alvaro Lassaletta; Blanca Lopez-Ibor; Elena Mateos; Marta Gonzalez-Vicent; Antonio Perez-Martinez; Julian Sevilla; Miguel A Diaz; Luis Madero
Journal:  J Neurooncol       Date:  2009-04-18       Impact factor: 4.130

Review 7.  Intrathecal drug delivery in the era of nanomedicine.

Authors:  M J Fowler; J D Cotter; B E Knight; E M Sevick-Muraca; D I Sandberg; R W Sirianni
Journal:  Adv Drug Deliv Rev       Date:  2020-03-03       Impact factor: 15.470

8.  Unusual causes of papilledema: Two illustrative cases.

Authors:  Ha Son Nguyen; Kathryn M Haider; Laurie L Ackerman
Journal:  Surg Neurol Int       Date:  2013-04-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.